Reported Saturday, Rhythm Pharmaceuticals Presents Phase 2 Data Showing Setmelanotide Achieves 3.06% Mean BMI Reduction And Clinically Meaningful Hyperphagia Improvements In Prader-Willi Syndrome Patients At ENDO 2026

Loading news article.

Reported Saturday, Rhythm Pharmaceuticals Presents Phase 2 Data Showing Setmelanotide Achieves 3.06% Mean BMI Reduction And Clinically Meaningful Hyperphagia Improvements In Prader-Willi Syndrome Patients At ENDO 2026 | WAPE

Reported Saturday, Rhythm Pharmaceuticals Presents Phase 2 Data Showing Setmelanotide Achieves 3.06% Mean BMI Reduction And Clinically Meaningful Hyperphagia Improvements In Prader-Willi Syndrome Patients At ENDO 2026

Article summary

Related companies

Comments —